Literature DB >> 22095961

Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma.

L S Hu1, J M Eschbacher, A C Dueck, J E Heiserman, S Liu, J P Karis, K A Smith, W R Shapiro, D S Pinnaduwage, S W Coons, P Nakaji, J Debbins, B G Feuerstein, L C Baxter.   

Abstract

BACKGROUND AND
PURPOSE: Quantifying MVA rather than MVD provides better correlation with survival in HGG. This is attributed to a specific "glomeruloid" vascular pattern, which is better characterized by vessel area than number. Despite its prognostic value, MVA quantification is laborious and clinically impractical. The DSC-MR imaging measure of rCBV offers the advantages of speed and convenience to overcome these limitations; however, clinical use of this technique depends on establishing accurate correlations between rCBV, MVA, and MVD, particularly in the setting of heterogeneous vascular size inherent to human HGG.
MATERIALS AND METHODS: We obtained preoperative 3T DSC-MR imaging in patients with HGG before stereotactic surgery. We histologically quantified MVA, MVD, and vascular size heterogeneity from CD34-stained 10-μm sections of stereotactic biopsies, and we coregistered biopsy locations with localized rCBV measurements. We statistically correlated rCBV, MVA, and MVD under conditions of high and low vascular-size heterogeneity and among tumor grades. We correlated all parameters with OS by using Cox regression.
RESULTS: We analyzed 38 biopsies from 24 subjects. rCBV correlated strongly with MVA (r = 0.83, P < .0001) but weakly with MVD (r = 0.32, P = .05), due to microvessel size heterogeneity. Among samples with more homogeneous vessel size, rCBV correlation with MVD improved (r = 0.56, P = .01). OS correlated with both rCBV (P = .02) and MVA (P = .01) but not with MVD (P = .17).
CONCLUSIONS: rCBV provides a reliable estimation of tumor MVA as a biomarker of glioma outcome. rCBV poorly estimates MVD in the presence of vessel size heterogeneity inherent to human HGG.

Entities:  

Mesh:

Year:  2011        PMID: 22095961      PMCID: PMC7966183          DOI: 10.3174/ajnr.A2743

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  49 in total

1.  Abnormalities of the contrast re-circulation phase in cerebral tumors demonstrated using dynamic susceptibility contrast-enhanced imaging: a possible marker of vascular tortuosity.

Authors:  A Kassner; D J Annesley; X P Zhu; K L Li; I D Kamaly-Asl; Y Watson; A Jackson
Journal:  J Magn Reson Imaging       Date:  2000-02       Impact factor: 4.813

2.  Prognostic implications of microvessel morphometry in diffuse astrocytic neoplasms.

Authors:  P Korkolopoulou; E Patsouris; N Kavantzas; A E Konstantinidou; P Christodoulou; E Thomas-Tsagli; A Pananikolaou; C Eftychiadis; P M Pavlopoulos; D Angelidakis; D Rologis; P Davaris
Journal:  Neuropathol Appl Neurobiol       Date:  2002-02       Impact factor: 8.090

3.  Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma.

Authors:  S I Abdulrauf; K Edvardsen; K L Ho; X Y Yang; J P Rock; M L Rosenblum
Journal:  J Neurosurg       Date:  1998-03       Impact factor: 5.115

4.  The vascular response to tumor infiltration in malignant gliomas. Morphometric and reconstruction study.

Authors:  D Schiffer; A Chiò; M T Giordana; A Mauro; A Migheli; M C Vigliani
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

5.  Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging.

Authors:  Andreas Stadlbauer; Oliver Ganslandt; Rolf Buslei; Thilo Hammen; Stephan Gruber; Ewald Moser; Michael Buchfelder; Erich Salomonowitz; Christopher Nimsky
Journal:  Radiology       Date:  2006-09       Impact factor: 11.105

6.  Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease?

Authors:  S Bisdas; M Kirkpatrick; P Giglio; C Welsh; M V Spampinato; Z Rumboldt
Journal:  AJNR Am J Neuroradiol       Date:  2009-01-29       Impact factor: 3.825

7.  Spin-echo echo-planar perfusion MR imaging in the differential diagnosis of solitary enhancing brain lesions: distinguishing solitary metastases from primary glioma.

Authors:  G S Young; K Setayesh
Journal:  AJNR Am J Neuroradiol       Date:  2008-12-18       Impact factor: 3.825

8.  Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.

Authors:  Weihua Liao; Yunhai Liu; Xiaoyi Wang; Xinya Jiang; Beisha Tang; Jiasheng Fang; Changqing Chen; Zhongliang Hu
Journal:  Acta Radiol       Date:  2009-03       Impact factor: 1.990

9.  Dynamic contrast-enhanced derived cerebral blood volume correlates better with leak correction than with no correction for vascular endothelial growth factor, microvascular density, and grading of astrocytoma.

Authors:  Mohammad Haris; Nuzhat Husain; Anup Singh; Mazhar Husain; Savita Srivastava; Chhitiz Srivastava; Sanjay Behari; Ram Kishore S Rathore; Sona Saksena; Rakesh Kumar Gupta
Journal:  J Comput Assist Tomogr       Date:  2008 Nov-Dec       Impact factor: 1.826

10.  Estimation of tumor microvessel density by MRI using a blood pool contrast agent.

Authors:  Fuminori Hyodo; Gadisetti V R Chandramouli; Shingo Matsumoto; Ken-Ichiro Matsumoto; James B Mitchell; Murali C Krishna; Jeeva P Munasinghe
Journal:  Int J Oncol       Date:  2009-10       Impact factor: 5.650

View more
  54 in total

Review 1.  Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions.

Authors:  Patrick Y Wen; Michael Weller; Eudocia Quant Lee; Brian M Alexander; Jill S Barnholtz-Sloan; Floris P Barthel; Tracy T Batchelor; Ranjit S Bindra; Susan M Chang; E Antonio Chiocca; Timothy F Cloughesy; John F DeGroot; Evanthia Galanis; Mark R Gilbert; Monika E Hegi; Craig Horbinski; Raymond Y Huang; Andrew B Lassman; Emilie Le Rhun; Michael Lim; Minesh P Mehta; Ingo K Mellinghoff; Giuseppe Minniti; David Nathanson; Michael Platten; Matthias Preusser; Patrick Roth; Marc Sanson; David Schiff; Susan C Short; Martin J B Taphoorn; Joerg-Christian Tonn; Jonathan Tsang; Roel G W Verhaak; Andreas von Deimling; Wolfgang Wick; Gelareh Zadeh; David A Reardon; Kenneth D Aldape; Martin J van den Bent
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

2.  Performance of Standardized Relative CBV for Quantifying Regional Histologic Tumor Burden in Recurrent High-Grade Glioma: Comparison against Normalized Relative CBV Using Image-Localized Stereotactic Biopsies.

Authors:  J M Hoxworth; J M Eschbacher; A C Gonzales; K W Singleton; G D Leon; K A Smith; A M Stokes; Y Zhou; G L Mazza; A B Porter; M M Mrugala; R S Zimmerman; B R Bendok; D P Patra; C Krishna; J L Boxerman; L C Baxter; K R Swanson; C C Quarles; K M Schmainda; L S Hu
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-12       Impact factor: 3.825

3.  Perfusion-metabolism coupling in recurrent gliomas: a prospective validation study with 13N-ammonia and 18F-fluorodeoxyglucose PET/CT.

Authors:  Bangkim Chandra Khangembam; Sellam Karunanithi; Punit Sharma; Sudhir Suman Kc; Rajeev Kumar; Pramod Kumar Julka; Rakesh Kumar; Chandrasekhar Bal
Journal:  Neuroradiology       Date:  2014-07-03       Impact factor: 2.804

4.  Perfusion imaging of brain gliomas using arterial spin labeling: correlation with histopathological vascular density in MRI-guided biopsies.

Authors:  Di Ningning; Pang Haopeng; Dang Xuefei; Cheng Wenna; Ren Yan; Wu Jingsong; Yao Chengjun; Yao Zhenwei; Feng Xiaoyuan
Journal:  Neuroradiology       Date:  2016-12-06       Impact factor: 2.804

5.  Ultrafast Dynamic Contrast-Enhanced Breast MRI: Kinetic Curve Assessment Using Empirical Mathematical Model Validated with Histological Microvessel Density.

Authors:  Naoko Mori; Hiroyuki Abe; Shunji Mugikura; Chiaki Takasawa; Satoko Sato; Minoru Miyashita; Yu Mori; Federico D Pineda; Gregory S Karczmar; Hajime Tamura; Shoki Takahashi; Kei Takase
Journal:  Acad Radiol       Date:  2018-09-28       Impact factor: 3.173

6.  Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low-Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors.

Authors:  K M Schmainda; M A Prah; L S Hu; C C Quarles; N Semmineh; S D Rand; J M Connelly; B Anderies; Y Zhou; Y Liu; B Logan; A Stokes; G Baird; J L Boxerman
Journal:  AJNR Am J Neuroradiol       Date:  2019-03-28       Impact factor: 3.825

7.  Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.

Authors:  Sina Burth; Philipp Kickingereder; Oliver Eidel; Diana Tichy; David Bonekamp; Lukas Weberling; Antje Wick; Sarah Löw; Anne Hertenstein; Martha Nowosielski; Heinz-Peter Schlemmer; Wolfgang Wick; Martin Bendszus; Alexander Radbruch
Journal:  Neuro Oncol       Date:  2016-06-13       Impact factor: 12.300

8.  Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.

Authors:  Philipp Kickingereder; Benedikt Wiestler; Sina Burth; Antje Wick; Martha Nowosielski; Sabine Heiland; Heinz-Peter Schlemmer; Wolfgang Wick; Martin Bendszus; Alexander Radbruch
Journal:  Neuro Oncol       Date:  2015-03-09       Impact factor: 12.300

9.  Pseudoprogression of glioblastoma after chemo- and radiation therapy: diagnosis by using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging with ferumoxytol versus gadoteridol and correlation with survival.

Authors:  Seymur Gahramanov; Leslie L Muldoon; Csanad G Varallyay; Xin Li; Dale F Kraemer; Rongwei Fu; Bronwyn E Hamilton; William D Rooney; Edward A Neuwelt
Journal:  Radiology       Date:  2012-11-30       Impact factor: 11.105

10.  Radiogenomics to characterize regional genetic heterogeneity in glioblastoma.

Authors:  Leland S Hu; Shuluo Ning; Jennifer M Eschbacher; Leslie C Baxter; Nathan Gaw; Sara Ranjbar; Jonathan Plasencia; Amylou C Dueck; Sen Peng; Kris A Smith; Peter Nakaji; John P Karis; C Chad Quarles; Teresa Wu; Joseph C Loftus; Robert B Jenkins; Hugues Sicotte; Thomas M Kollmeyer; Brian P O'Neill; William Elmquist; Joseph M Hoxworth; David Frakes; Jann Sarkaria; Kristin R Swanson; Nhan L Tran; Jing Li; J Ross Mitchell
Journal:  Neuro Oncol       Date:  2016-08-08       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.